Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: Angiopeptin; Lanreotide; Somatostatin

Criteria

Inclusion Criteria:

• Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease

• No hormone related symptoms

• Well or moderately differentiated tumour confirmed by histology

• Tumour lesions which are measurable by a CT or MRI scan

Exclusion Criteria:

• Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days

• Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide

• Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years

• Pregnant or lactating

• Females must use adequate contraception during the study